NeoNeuro was created to focus the aptamer expertise of NeoVentures Biotechnology Inc (Aptamer development company in London, Canada) with the neurological expertise and resources of the L’Institut du Cerveau et de la Moelle épinière (ICM) in Paris, France. NeoNeuro is registered in Paris, and all research activities are currently taking place within ICM facilities at l’Hôpital Pitié Salpêtrière in Paris. NeoNeuro is focused on the development of aptamer based solutions for the treatment and diagnosis of Alzheimer’s disease.
NeoVentures has licensed proprietary platforms including their free/free selection approach FRELEX to NeoNeuro for neurological applications.
For more information on aptamers in general please visit www.neoventures.ca
The Institut du Cerveau et de la Moelle épinière – ICM (Brain & Spine Institute) – is an international brain and spinal cord research center whose innovative concept and structure make it the only institute of its kind in the world. The ICM brings patients, doctors and researchers together with the aim of rapidly develop treatments for disorders of the nervous system and enable patients to benefit from them as quickly as possible.The best scientists from all backgrounds and countries come together at the Institute to perform leading-edge research in this area.